Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Publié en ligne: 17 mars 2022

Pages: 56 - 65

Reçu: 22 juin 2021

DOI: https://doi.org/10.2478/rjim-2021-0034

Mots clés

atypical hemolytic uremic syndrome, eculizumab, therapeutic plasma exchange, discontinuation, prognosis

© 2022 Hasan H. Yeter et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.